NervGen Pharma Corp.
NGENHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NervGen Pharma Corp. focuses on Biotechnology services and products. NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma. The company carries a $250.5M market cap, placing it firmly in the micro-cap category. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Market Cap
$250.5M
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
-6.83
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.34
ROE
-757.5%
ROA
-37.7%
Cash
$86.8M
Total Debt
$0
Free CF
$38.4M
52W Change
-13.1%
Annual Financials
Cash vs Debt
Where NGEN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NGEN finished 22.07% below its 150-day moving average ($2.99) and 31.07% below its 200-day moving average ($3.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NGEN overbought or oversold?
At the September 3, 2026 close, NGEN's RSI(14) was 79.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NervGen Pharma Corp. reports $86.8M in cash and $0 in total debt. Free cash flow comes in at $38.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -757.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
As with any equity investment, NGEN carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing NGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.